Merck & Co., Inc. — Director's Dealing 2022

Feb 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Merck & Co., Inc. (MRK)
CIK: 0000310158
Period of Report: 2021-02-10

Reporting Person: Williams David Michael (EVP,Chief Info&Digital Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-10	Common Stock	M	1167	$75.04	Acquired	3659.883	Direct
2021-02-10	Common Stock	F	467	$75.04	Disposed	3192.883	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-10	Restricted Stock Unit	$	M	1167	Disposed	2023-02-10	Common Stock (1167)	Direct

Footnotes

F1: Holdings include shares acquired in dividend reinvestment transactions; reflects holdings as of February 10, 2021.

F2: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F3: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 2/10/2021, 2/10/2022 and 2/10/2023.

F4: Holdings were adjusted to 2,407 as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.